EUVIMEDEUVIMED entdecken
Crossref

Microporous annealed particle scaffold integrated with autologous tumor cells for personalized postsurgical tumor therapy

Gaizhen Kuang, Wenzhao Li, Feika Bian, Hong Chen, Qingfei Zhang, Yuanjin Zhao

Acta Biomaterialia · 2026-09 · 222 · 450-459

DOI: 10.1016/j.actbio.2026.07.052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-09. Verfasst von Gaizhen Kuang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, China. Hauptthemen laut MEDLINE: Tissue Scaffolds, Precision Medicine, Melanoma, Experimental. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China Stem Cell and Translational Research, Zhejiang Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomaterial scaffolds hold great potential for addressing tumor recurrence and tissue defects following surgical tumor resection; however, personalized therapy remains a critical barrier to their clinical translation. To address this issue, we developed an autologous tumor cell-integrated microporous annealed particle (MAP) scaffold co-delivering an immune adjuvant and an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor for tumor postoperative therapy. This scaffold was fabricated using microfluidic electrospray combined with step-by-step crosslinking technology. The injectable microspheres, prior to annealing, can be directly delivered into the defect site and conform to its shape upon crosslinking, forming a stabilized, porous structure. Featuring interconnected pores that facilitate cell infiltration and proliferation, the scaffold demonstrated effective tissue repair in mice subjected to full-thickness skin excision. Within the scaffold, cryo-inactivated tumor cells and the immune adjuvant recruit and activate dendritic cells (DCs) in situ, stimulating a robust antitumor immune response. This response is further amplified by the IDO1 inhibitor, which reverses immunosuppression by inhibiting regulatory T cells (Tregs). Consequently, the scaffold exhibited remarkable anti-recurrence efficacy and prolonged survival in a melanoma mouse model. These properties highlight the significant potential of our personalized microporous hydrogel particle scaffold for efficient postoperative antitumor therapy and tissue regeneration. STATEMENT OF SIGNIFICANCE: Tumor recurrence and tissue defects represent significant challenges following surgical tumor removal in cancer patients. Meanwhile, a critical barrier to the clinical translation of postoperative biomaterial scaffolds is the lack of personalization for both antitumor therapy and tissue reconstruction. Here, we developed a personalized microporous annealed particle (MAP) scaffold that integrates autologous tumor cells, immune adjuvant, and IDO1 inhibitor to simultaneously address tumor recurrence and tissue defects. Personalized antitumor therapy is achieved by the injectable MAP scaffold through a tumor vaccine formed from autologous tumor-derived cells within the scaffold, eliciting tumor-specific T-cell responses that are further amplified by reversing the local immunosuppressive microenvironment. Personalized tissue repair is also enabled by such scaffold, which conforms to irregular wound shapes and supports cell infiltration. This work establishes a paradigm that unifies personalized immunotherapy with personalized tissue repair, offering substantial promise for postsurgical cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue ScaffoldsPrecision MedicineMelanoma, ExperimentalAnimalsPorosityMiceCell Line, TumorIndoleamine-Pyrrole 2,3,-DioxygenaseMice, Inbred C57BLHumansFemaleDendritic Cells

Stichwörter der Autor:innen

Biomaterial scaffoldCancer vaccineImmunotherapyMicrofluidicsPersonalized therapyTissue engineering

Substanzen

Indoleamine-Pyrrole 2,3,-Dioxygenase

Autor:innen und Institutionen

  • Department of Radiation and Medical Oncology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, China.
  • Department of Otolaryngology Head and Neck Surgery, Nanjing Drum Tower Hospital, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China; Department of Biomedical Engineering, T…
  • Department of Otolaryngology Head and Neck Surgery, Nanjing Drum Tower Hospital, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. Electronic address: 541749457@qq.com.
  • Department of Radiation and Medical Oncology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, China; School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325000, China. Electr…
  • Department of Radiation and Medical Oncology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, China; Department of Otolaryngology Head and Neck Surgery, Nanjing Drum Tower Hospital, School of…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • Zhejiang Province Natural Science Foundation

Zitieren

APA

Kuang, G., Li, W., Bian, F., Chen, H., Zhang, Q., & Zhao, Y. (2026). Microporous annealed particle scaffold integrated with autologous tumor cells for personalized postsurgical tumor therapy. Acta Biomaterialia, 222, 450-459. https://doi.org/10.1016/j.actbio.2026.07.052

Vancouver

Kuang G, Li W, Bian F, Chen H, Zhang Q, Zhao Y. Microporous annealed particle scaffold integrated with autologous tumor cells for personalized postsurgical tumor therapy. Acta Biomaterialia. 2026;222:450-459. doi:10.1016/j.actbio.2026.07.052

BibTeX
@article{Kuang2026,
  author = {Kuang, Gaizhen and Li, Wenzhao and Bian, Feika and Chen, Hong and Zhang, Qingfei and Zhao, Yuanjin},
  title = {Microporous annealed particle scaffold integrated with autologous tumor cells for personalized postsurgical tumor therapy},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {222},
  pages = {450--459},
  doi = {10.1016/j.actbio.2026.07.052}
}
Kostenlos starten →